• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, November 17, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Nomogram Predicts Early Treatment Failure in Diffuse Large B-Cell Lymphoma Patients

by
November 17, 2026
in Health
Reading Time: 3 mins read
0
Nomogram Predicts Early Treatment Failure in Diffuse Large B-Cell Lymphoma Patients

Nomogram Predicts Early Treatment Failure in Diffuse Large B-Cell Lymphoma Patients

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A new clinical-laboratory nomogram has been developed and internally validated to help identify patients with diffuse large B-cell lymphoma (DLBCL) who are at high risk of experiencing primary refractory disease or early relapse following standard first-line R-CHOP immunochemotherapy.

First-line R-CHOP immunochemotherapy controls diffuse large B-cell lymphoma in most patients, but 30% to 40% develop primary refractory disease or early relapse. Refractory disease and early relapse, which occur in a substantial subset of patients, are both associated with poor survival outcomes. The International Prognostic Index captures tumor biology only partially, and no bedside tool integrates routine inflammatory, metabolic, and proliferative markers. The resulting nomogram incorporates six specific routine laboratory markers: lactate dehydrogenase (LDH), β2-microglobulin (β2-MG), the neutrophil-to-lymphocyte ratio (NLR), the platelet-to-lymphocyte ratio (PLR), Ki-67, and the lymphocyte-to-monocyte ratio (LMR).

The study was designed as a retrospective analysis where the total cohort of 342 patients was randomly partitioned into a training cohort consisting of 239 individuals and an internal validation cohort of 103 individuals, maintaining a 7:3 ratio. The research team first conducted a univariate analysis to screen for potential predictors, requiring a P-value of less than 0.05 to retain candidate variables. Univariate analysis was followed by LASSO and multivariable logistic regression.

To rigorously evaluate the predictive power of their chosen logistic regression model, the team compared it against other common machine learning approaches, including random forest (RF) and support vector machines (SVM). Performance was assessed using a variety of metrics, including the area under the receiver operating characteristic curve (ROC-AUC), calibration plots, and decision curve analysis. Furthermore, SHAP analysis was used to quantify predictor contributions on the log-odds scale.

The findings indicated that elevated levels of LDH, β2-MG, NLR, PLR, and Ki-67, coupled with reduced levels of LMR, were independent predictors of early treatment failure. The logistic regression model achieved an AUC of 0.815 in the training cohort, with a 95% confidence interval ranging from 0.747 to 0.883, and maintained a performance of 0.776 in the validation cohort. There were no significant between-model AUC differences, and the logistic model was selected for parsimony and interpretability.

Assessment of the model’s reliability showed that the calibration slopes and intercepts were 0.97 and 0.03 in the training set, and 0.93 and 0.07 in the validation set, indicating that the nomogram’s predictions align closely with the observed outcomes. Decision curve analysis further demonstrated the clinical utility of the model, revealing positive net benefits at risk thresholds of 0.2, 0.3, and 0.4.

Despite these promising results, the study authors emphasize that the current nomogram remains an exploratory tool. A critical limitation of this research is that it was restricted to a single-center cohort, which may limit the generalizability of the findings across more diverse patient populations treated in different clinical environments. Moreover, the model was not formally benchmarked against established clinical prognostic systems such as the standard IPI, NCCN-IPI, or R-IPI.

For this nomogram to transition into actual clinical use, it requires extensive multicenter prospective external validation.

Subject of Research: Clinical research on a predictive nomogram for early treatment failure in DLBCL.

Article Title: A clinical-laboratory nomogram integrating inflammatory, metabolic and proliferative markers to predict refractory disease or early relapse in diffuse large B-cell lymphoma

Article References: Li, S., Yang, Q., Zhang, W., & Chen, W. (2026). A clinical-laboratory nomogram integrating inflammatory, metabolic and proliferative markers to predict refractory disease or early relapse in diffuse large B-cell lymphoma. Frontiers in Medicine, 13, Article 1995591. https://doi.org/10.3389/fmed.2026.1995591

Image Credits: AI Generated

DOI: 10.3389/fmed.2026.1995591

Keywords: Diffuse large B-cell lymphoma, DLBCL, R-CHOP, immunochemotherapy, refractory disease, early relapse, oncology, clinical prognosis, biomarker, nomogram, LDH, beta-2 microglobulin, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, Ki-67, lymphocyte-to-monocyte ratio, machine learning, clinical prediction model, hematology

News Source: Nathaniel Bowman. (November 17, 2026). Nomogram Predicts Early Treatment Failure in Diffuse Large B-Cell Lymphoma Patients. Scienmag.

Tags: beta-2-microglobulinbiomarkerclinical prediction modelclinical prognosisdiffuse large B-cell lymphomaDLBCLearly relapseHematologyimmunochemotherapyKi-67LDHlymphocyte-to-monocyte ratioMachine LearningNeutrophil-to-lymphocyte rationomogramOncologyPlatelet-to-lymphocyte ratioR-CHOPrefractory disease
Share12Tweet7Share2ShareShareShare1

Related Posts

Professional Footballers Experience Sustained Career Declines After ACL Reconstruction

Professional Footballers Experience Sustained Career Declines After ACL Reconstruction

November 17, 2026
Postoperative Alignment Influences Long-Term Knee Revision Risk Following High Tibial Osteotomy

Postoperative Alignment Influences Long-Term Knee Revision Risk Following High Tibial Osteotomy

November 17, 2026

Diagnosing Rare Thrombotic Microangiopathy in Systemic Lupus and Scleroderma Overlap Syndrome

November 17, 2026

Swedish Log Truck Drivers Spend Most Workdays Sedentary and Miss Exercise Guidelines

November 17, 2026

POPULAR NEWS

  • High Prevalence of Gender-Based Violence Follows Armed Conflict in Southern Tigray

    High Prevalence of Gender-Based Violence Follows Armed Conflict in Southern Tigray

    29 shares
    Share 12 Tweet 7
  • Air Pollutants Tied to Adverse Sleep Outcomes Amid Notable Evidence Uncertainty

    29 shares
    Share 12 Tweet 7
  • Network Analysis Identifies Core Positive Development Attributes in Rural Chinese Adolescents

    29 shares
    Share 12 Tweet 7
  • China Silver Economy Policies Show Good Overall Consistency but Uneven Regional Breadth

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Professional Footballers Experience Sustained Career Declines After ACL Reconstruction

Postoperative Alignment Influences Long-Term Knee Revision Risk Following High Tibial Osteotomy

Proposed Biogas Systems Could Cut Egyptian Household Energy Costs by 35–40%

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.